Moderna and Merck report progress in experimental cancer treatments. Moderna pivoted its work toward cancer treatments, sending its stock up 177%. The company developed a custom mRNA treatment designed to combat skin cancer, though its effectiveness has yet to be fully proven. Merck developed a cancer vaccine that could pave the way for a wave of related medical developments.
Views on these developments vary. Certain experts attribute success to private sector competition, while others view it as an overdue advance. Additional testing is needed to clearly determine the implications of these findings. Still, the results signal a promising direction in cancer treatment.